Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
| Previous close | 212.60 |
| Open | 214.80 |
| Bid | 209.20 x 0 |
| Ask | 209.50 x 0 |
| Day's range | 208.50 - 215.00 |
| 52-week range | 139.55 - 245.40 |
| Volume | |
| Avg. volume | 583,255 |
| Market cap | 62.101B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | 24.67 |
| EPS (TTM) | 8.53 |
| Earnings date | 19 Jul 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 246.75 |
- Zacks
Apellis (APLS) Hit By Wider-Than-Expected Q1 Loss, Revenues Top
Apellis' (APLS) earnings missed estimates in the first quarter of 2022, while revenues surpassed expectations.
- Reuters
Drugmaker Sobi books profit fall on restructuring, Russia
Swedish Orphan Biovitrum (Sobi) on Thursday reported a smaller-than-expected first-quarter operating profit and said sales grew in emerging markets for its drug Kineret for the treatment of COVID-19. The rare disease drugmaker's operating profit fell to 776 million crowns ($78.6 million) from 1.03 billion and missed the 1.16 billion expected by analysts polled by Refinitiv. The group, which sells drugs targeted at haemophilia, autoimmune diseases, metabolic diseases and cancer supportive care, booked restructuring costs of 507 million and a 157 million provision for expected credit losses in Russia.
- Zacks
Apellis (APLS) Q4 Loss Widens, Revenues Surpass Estimates
Apellis' (APLS) earnings miss estimates in the fourth quarter of 2021, while revenues surpass expectations.
